Mifepristone (RU486): A review

Fertility and Sterility

Volumn 68, Issue 6, 1997, Pages 967-976

  Mahajan, Damodar K ^a   London, Steve N ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Abortifacient; Antiprogestins; Breast cancer; Cervical ripening; Contraceptive; Endometriosis; Labor induction; Leiomyoma; Mifepristone; RU486

Indexed keywords

GLUCOCORTICOID RECEPTOR; MIFEPRISTONE;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; DATA ANALYSIS; ENDOMETRIOSIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEIOMYOMA; MEDICAL RESEARCH; MENINGIOMA; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW;

EID: 0031437016     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)00189-1     Document Type: Article

References (80)

1. 1. Pincus G. The control of fertility. New York: Academic Press, 1965:128-38.
2. 2. Belanger A, Philibert D, Teutsch G. Regio and stereospecific synthesis of 11β-substituted 19-norsteroids. Steroids 1981; 37:361-82.
3. 3. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9:1603-14.
4. 4. Fawell SE, Lees JA, White R, Parker MG. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 1990;60:953-62.
5. 5. Baulieu EE. On the mechanism of action of RU486. In: Seppala M, Hamberger L, editors. Frontiers in human reproduction. Ann NY Acad Sci 1991;626:545-6.
6. 6. Sheridan PL, Evans RM, Horwitz KB. Phosphotryptic peptide analysis of human progesterone receptor: new phosphorylated sites formed in nuclei after hormone treatment. J Biol Chem 1989;264:6520-8.
7. 7. Skafar DF. Differences in the binding mechanism of RU486 and progesterone to the progesterone receptors. Biochemistry 1991;30:10829-31.
8. 8. Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L. Pharmacokinetics and metabolism of RU486. J Steroid Biochem 1987;27:859-63.
9. 9. Swahn ML, Wang G, Aedo AR, Cekan SZ, Bygdeman M, Plasma levels of antiprogestin RU486 following oral administration to non-pregnant and early pregnant women. Contraception 1986;34:469-81.
10. 10. Heikinheimo O, Lahteenmaki P, Koivunen E, Shope D, Croxatto H, Luukkainen T, et al. Metabolism and serum binding of RU486 in women after various single doses. Hum Reprod 1987;2:379-85.
11. 11. Frydman R, Taylor S, Ulmann A. Transplacental passage of mifepristone. Lancet 1985;2:1252.
12. 12. Hill NCW, Selinger M, Ferguson J, MacKenzie IZ. The placental transfer of mifepristone (RU486) during the second trimester and its influence upon maternal and fetal steroid concentrations. Br J Obstet Gynaecol 1990;97:406-11.
13. 13. Stuenkel CA, Garzo VG, Morris S, Liu JH, Yen SSC. Effect of antiprogesterone RU486 in early follicular phase of the menstrual cycle. Fertil Steril 1990;53:642-6.
14. 14. Liu JH, Garzo VG, Morris S, Stuenkel CA, Ulmann A, Yen SSC. Disruption of follicular maturation and delay of ovulation after administration of antiprogesterone RU486. J Clin Endocrinol Metab 1987;65:1135-40.
15. 15. Shoupe D, Mishell DR, Page MA, Madkour H, Spitz IM, Lobo RA. Effect of antiprogesterone RU486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol 1987;157:1421-6.
16. 16. Luukkainen T, Heikinheimo O, Haukkamaa M, Lahteenmaki P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU486. Fertil Steril 1988;49:961-8.
17. 17. Permezel JM, Lenton EA, Roberts I, Cooke ID. Acute effect of progesterone and the antiprogestin RU486 on gonadotropin secretion in the follicular phase of the menstrual cycle. J Clin Endocrinol Metab 1989;68:960-5.
18. 18. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Loriaux DL, Merriam GR. The antiprogestin RU486 delays the midcycle surge and ovulation in gonadotropin releasing hormone-induced cycles. Fertil Steril 1994;62:28-34.
19. 19. Brogden RN, Goa KL, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1993;45:384-409.
20. 20. Birgerson L, Odlind V. Early pregnancy termination with anti-progestin: a comparative clinical study of RU486 given in two dose regimens and Epostane. Fertil Steril 1987;48: 565-70.
21. 21. Kovacs L, Sas M, Resch BA, Ugocsai G, Swahn ML, Bygdeman M, et al. Termination of very early pregnancy by RU486 - an antiprogestational compound. Contraception 1984;29:399-409.
22. 22. Mishell DR Jr, Shoupe D, Brenner PF, Lacarra M, Horenstein J, Lahteenmaki P, et al. Termination of early gestation with the anti-progestin steroid RU486: medium versus low dose. Contraception 1987;35:307-21.
23. 23. Vervest HAM, Haspels AA. Preliminary results with the antiprogestational compound RU486 (mifepristone) for interruption of early pregnancy. Fertil Steril 1985;44:627-32.
24. 24. Grimes DA, Mishell DR Jr, Shoupe D, Lacarra M. Early abortion with a single dose of antiprogestin RU486. Am J Obstet Gynecol 1988;158:1307-12.
25. 25. Shu-rong Z. RU486 (mifepristone) clinical trials in China. Acta Obstet Gynecol Scand 1989;149:19-23.
26. 26. Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985;32:45-51.
27. 27. Cameron IT, Michie AF, Baird DT. Therapeutic abortion in early pregnancy with antiprogesterone RU486 alone or in combination with prostaglandin analog (Gerneprost). Contraception 1986;34:459-68.
28. 28. Rodger MW, Baird DT. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987;2:1415-8.
29. 29. Dubois C, Ulmann A, Aubeny E, Elia D, Jourdan MC, Van den Bosch MC, et al. Contragestion par le RU486: interet de l'association un derive prostaglandine. C R Acad Sci 1988; 306:57-61.
30. 1 analogue vaginal pessary for the termination of early pregnancy: complication and patients' acceptability. Am J Obstet Gynecol 1990;162:414-7.
31. 1 analogue) alone and mifepristone and gemeprost. Br J Obstet Gynaecol 1992;99:601-6.
32. 32. Maurice J. WHO suggests lower dose of mifepristone. Br Med J 1991;303:944.
33. 33. WHO Task Force. Early pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertil Steril 1991;56:32-40.
34. 34. Urquhart DR, Templeton AA. Mifepristone (RU486) and second trimester termination. Lancet 1987;2:1405-6.
35. 35. Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU486) prior to prostaglandin termination of pregnancy. Hum Reprod 1989;4:202-3.
36. 36. Rodger MW, Baird DT. Pretreatment with mifepristone (RU486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynaecol 1990;97:41-5.
37. 37. Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Hum Reprod 1990;5:883-6.
38. 38. Pons JC, Rais S, Diochin P, Frydman R. RU486 (mifepristone) et interruption volontaire ed grossesse pour motif therapeutique an deuxieme et troisieme trimestre. J Gynecol Obstet Biol Reprod (Paris) 1992;21:255-7.
39. 39. Gottlieb C, Bygdeman M. The use of antiprogestin (RU486.) for termination of second trimester pregnancy. Acta Obstet Gynecol Scand 1991;70:199-203.
40. 40. Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for termination of second trimester pregnancy. Contraception 1992;46:11-7.
41. 41. Stiemer B, Elger W, Cervical ripening of the rat in dependence of endocrine milieu: effect of antiprogestins. J Perinat Med 1990;18:419-29.
42. 42. Cabrol D, Carbonne B, Bienkiewicz A, Dallat E, Alj AE, Cedard L. Induction of labor and cervical maturation using mifepristone (RU486) in the late pregnant rat. Influence of a cyclooxygenase inhibitor (Diclofenac). Prostaglandins 1991; 42:71-9.
43. 43. Ikuta Y, Matsuura K, Okamura H, Oyamada I, Usuku G. Effects of RU486 on the interstitial collagenase in the process of cervical ripening in the pregnant rat. Endocrinol Jpn 1991;38:491-6.
44. 44. Wolf JP, Sinocich M, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD. Progesterone antagonist (RU486) for cervical dilation, labor induction, and delivery in monkeys: effectiveness in combination with oxytocin. Am J Obstet Gynecol 1989;160:45-7.
45. 45. Ulmann A, Silvestre L. Use of antiprogestins after 63 days of amenorrhea. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical application of mifepristone (RU486) and other antiprogestins. Washington, DC: National Academy Press, 1993:174-82.
46. 46. Lefebvre Y, Proulx L, Elie R, Poulin O, Lanza E. The effects of RU-38486 on cervical ripening: clinical studies. Am J Obstet Gynecol 1990;162:61-5.
47. 47. World Health Organization. The use of mifepristone (RU486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration. Br J Obstet Gynaecol 1990; 97:260-6.
48. 48. Radestad A, Christensen NJ, Stromberg L. Induced cervical ripening with mifepristone in first trimester abortion. A double-blind randomized biochemical study. Contraception 1988; 38:301-12.
49. 49. Gupta JK, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet 1990;335: 1238-40.
50. 50. Henshaw RC, Templeton AA. Preoperative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU486). Br J Obstet Gynaecol 1991;98:1025-30.
51. 51. Frydman R, Lelaidier C, Baton-Saint-Mieux C, Fernandez H, Vial M, Bourget P. Labour induction in women at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992;80:972-5.
52. 52. Van Look PF, Bygdman M. Antiprogestational steroids: a new dimension in human fertility regulation. Oxf Rev Reprod Biol 1989;11:2-60.
53. 53. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 1991;337: 1414-5.
54. 54. Webb AMC. Alternative treatments in oral postcoital contraception: interim results. Adv Contracept 1991;7:271-9.
55. 55. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone (RU486) compared with high dose estrogen and progestogen for emergency postcoital treatment. N Engl J Med 1992;327:1041-4.
56. 56. Webb AMC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception. Br Med J 1992;305:927-31.
57. 57. Swahn ML, Gemzell K, Bygdeman M. Contraception with mifepristone [letter]. Lancet 1991;338:942-3.
58. 58. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet Gynecol 1980;55:20-4.
59. 59. Schaison G, George M, Lestrate N, Reinberg A, Baulieu EE. Effect of the antiprogesterone RU486 during mid luteal phase in normal woman. J Clin Endocrinol Metab 1985;61:484-9.
60. 60. Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SSC. Effects of antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 1988;66:508-17.
61. 61. Luukkainen T, Heikinheimo O, Haukkamaa M, Lahteenmaki P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU486. Fertil Steril 1988;49:961-3.
62. 62. Roseff SJ, Kettel LM, Rivier J, Burger HG, Baulieu E, Yen SSC. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonist of gonadotropin-releasing hormone and progesterone to late-luteal phase women. Fertil Steril 1990;54:805-10.
63. 63. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SSC. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J Clin Endocrinol Metab 1993;76:513-7.
64. 64. Murphy AA, Castellano PZ. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata. Curr Opin Obstet Gynecol 1994;6:269-76.
65. 65. Yen SSC. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical applications of mifepristone (RU486) and other antiprogestins. Washington, DC: National Academy Press, 1993:189-209.
66. 66. Lessey BA, Melzger DA, Haney AF, McCarty KS. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 1989;51:409-15.
67. 67. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SSC. Endocrine responses to long-term administration of the antiprogesterone RU486 in patient with pelvic endometriosis. Fertil Steril 1991;56:402-7.
68. 68. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SSC. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8.
69. 69. Meyer JS. Cell proliferation in normal human breast ducts, fibroadenomas and other ductal hyperplasias measured by nuclear labelling with tritiated thymidine. Hum Pathol 1977; 8:67-81.
70. 70. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-93.
71. 71. Li M, Spitzer E, Zschiesche W, Binas B, Parcczyk K, Gross R. Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland. J Cell Physiol 1995; 164:1-8.
72. 72. Horowitz KB. Antiprogestins and the treatment of breast cancer. In: Donaldson MS, Dorflinger L, Benet LZ, editors. Clinical applications of mifepristone (RU486) and other antiprogestins. Washington, DC: National Academy Press, 1993: 210-28.
73. 73. Maudelonde T, Romieu G, Ulman A, Pujol H, Grenier J, Khalaf S, et al. First clinical trial on the use of antiprogestin RU486 in advanced breast cancer. In: Klijn JGM, Paridaens R, Foekens JA, editors. Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. New York: Raven Press, 1987:55-9.
74. 74. Michno H, Schneider MR, Nishino Y, El Etreby FM. Antitumor activity of antiprogestins ZK98.299 and RU38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 1989;14:275-88.
75. 75. Bakker GH, Setyno-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem 1990;37:789-94.
76. 76. Grunberg SM. Role of progestational therapy for meningiomas. Hum Reprod 1994;9(Suppl):202-7.
77. 77. Van Seters AP, Dulkins H, de Keizer RJW, Vievoye GJ. Symptomatic relief of meningioma by buserelin maintenance therapy. Lancet 1989;1:564-5.
78. 78. Grunberg SM, Weiss MH, Spitz IM, Ahamadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone mifepristone. J Neurosurg 1991; 74:861-6.
79. 79. Lamberts SWJ, Tanghe HLJ, Avezaat CJJ, Braakman R, Wijngaard R, Koper LW, et al. Mifepristone (RU486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 1992;55: 486-90.
80. 80. Haak HR, de Keizer RJW, Hagenouw-Taal JCW, van Seters AP, Vielvoye GJ, van Dulken H. Successful treatment of recurrent inoperable meningioma. Lancet 1990;336:124-5.